TY - JOUR
T1 - P.Ala541Thr variant of MEN1 gene
T2 - A non deleterious polymorphism or a pathogenic mutation?
AU - The Groupe français des tumeurs endocrines (GTE)
AU - Nozières, Cecile
AU - Zhang, Chang Xian
AU - Buffet, Alexandre
AU - Dupasquier, Stéphanie
AU - Vargas-Poussou, Rosa
AU - Guillaud-Bataille, Marine
AU - Cordier-Bussat, Martine
AU - Ruszniewski, Philippe
AU - Christin-Maitre, Sophie
AU - Murat, Arnaud
AU - Groussin, Lionel
AU - Vezzosi, Delphine
AU - Cardot-Bauters, Catherine
AU - Hervieu, Valérie
AU - Joly, Marie Odile
AU - Giraud, Sophie
AU - Odou, Marie Françoise
AU - Gimenez-Roqueplo, Anne Paule
AU - Goudet, Pierre
AU - Borson-Chazot, Françoise
AU - Calender, Alain
AU - Sarfati, E.
AU - Caron, P.
AU - Krivstky, A.
AU - Bertagna, F.
AU - Brunaud, L.
AU - Levy, P.
AU - Peix, J. L.
AU - Rohmer, V.
AU - Delemer, B.
AU - Houllier, P.
AU - de Boisvilliers, F.
AU - Galinat, S.
AU - Wojtusciszyn, A.
AU - Verier-Mine, O.
AU - Reffet, S.
AU - Khiter, C.
AU - Carpentier, B.
AU - Ronci-Chaix, N.
AU - Guignat, L.
AU - Baudry, A.
AU - Nion-Larmurier, I.
AU - Vacher-Lavenu, M. C.
AU - Berger, F.
AU - Costes-Martineau, V.
AU - Delisle, B.
AU - Cezard, J. P.
AU - Parfait, B.
AU - Barlier, A.
AU - Baudin, E.
N1 - Publisher Copyright:
© 2014 Elsevier Masson SAS.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Multiple Endocrine Neoplasia Type 1 (MEN1) is an autosomal dominant inherited syndrome, related to mutations in the MEN1 gene. Controversial data suggest that the nonsynonymous p.Ala541Thr variant, usually considered as a non-pathogenic polymorphism, may be associated with an increased risk of MEN1-related lesions in carriers. Objective: The aim of this study was to evaluate the pathogenic influence of the p.Ala541Thr variant on clinical and functional outcomes. Patients and methods: We analysed a series of 55 index patients carrying the p.Ala541Thr variant. Their clinical profile was compared to that of 117 MEN1 patients. The biological impact of the p.Ala541Thr variant on cell growth was additionally investigated on menin-deficient Leydig cell tumour (LCT)10 cells generated from Men1+/Men1- heterozygous knock-out mice, and compared with wild type (WT). Results: The mean age at first appearance of endocrine lesions was similar in both p.Ala541Thr carriers and MEN1 patients, but no p.Ala541Thr patient had more than one cardinal MEN1 lesion at initial diagnosis. A second MEN1 lesion was diagnosed in 13% of MEN1 patients and in 7% of p.Ala541Thr carriers in the year following preliminary diagnosis. Functional studies on LCT10 cells showed that overexpression of the p.Ala541Thr variant did not inhibit cell growth, which is in direct contrast to results obtained from investigation of WT menin protein. Conclusion: Taken together, these data raise the question of a potential pathogenicity of the p.Ala541Thr missense variant of menin that commonly occurs within the general population. Additional studies are required to investigate whether it may be involved in a low-penetrance MEN1 phenotype.
AB - Multiple Endocrine Neoplasia Type 1 (MEN1) is an autosomal dominant inherited syndrome, related to mutations in the MEN1 gene. Controversial data suggest that the nonsynonymous p.Ala541Thr variant, usually considered as a non-pathogenic polymorphism, may be associated with an increased risk of MEN1-related lesions in carriers. Objective: The aim of this study was to evaluate the pathogenic influence of the p.Ala541Thr variant on clinical and functional outcomes. Patients and methods: We analysed a series of 55 index patients carrying the p.Ala541Thr variant. Their clinical profile was compared to that of 117 MEN1 patients. The biological impact of the p.Ala541Thr variant on cell growth was additionally investigated on menin-deficient Leydig cell tumour (LCT)10 cells generated from Men1+/Men1- heterozygous knock-out mice, and compared with wild type (WT). Results: The mean age at first appearance of endocrine lesions was similar in both p.Ala541Thr carriers and MEN1 patients, but no p.Ala541Thr patient had more than one cardinal MEN1 lesion at initial diagnosis. A second MEN1 lesion was diagnosed in 13% of MEN1 patients and in 7% of p.Ala541Thr carriers in the year following preliminary diagnosis. Functional studies on LCT10 cells showed that overexpression of the p.Ala541Thr variant did not inhibit cell growth, which is in direct contrast to results obtained from investigation of WT menin protein. Conclusion: Taken together, these data raise the question of a potential pathogenicity of the p.Ala541Thr missense variant of menin that commonly occurs within the general population. Additional studies are required to investigate whether it may be involved in a low-penetrance MEN1 phenotype.
KW - Multiple endocrine neoplasia type 1
KW - Mutation
KW - Penetrance
KW - Polymorphism
KW - Predisposition
UR - http://www.scopus.com/inward/record.url?scp=84923069353&partnerID=8YFLogxK
U2 - 10.1016/j.ando.2014.05.003
DO - 10.1016/j.ando.2014.05.003
M3 - Article
C2 - 24997771
AN - SCOPUS:84923069353
SN - 0003-4266
VL - 75
SP - 133
EP - 140
JO - Annales d'Endocrinologie
JF - Annales d'Endocrinologie
IS - 3
ER -